What Seagen’s Pipeline Will Bring To Pfizer
Executive Summary
Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.
You may also be interested in...
William Pao On Pfizer’s ‘Aspirational’ Drug Development Goal, Seagen And More
Chief development officer William Pao oversees Pfizer’s clinical pipeline. He joined the company from Roche following a career in academia, and after his first year at Pfizer talked to Scrip about the transition to late-stage drug development.
Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review
Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.
BioNTech Gets In On ADC Action With DualityBio Licensing Deal
The German biotech is spending some of its pandemic capital on two antibody-drug conjugate candidates from the Chinese firm, including one in Phase II development.